The Oxford coronavirus vaccine produces a strong immune response in older adults, according to the latest trial results.The University of Oxford is expected to release full data on the effectiveness of the vaccine in the coming weeks.Phase two data, published in The Lancet, suggests the ChAdOx1 nCov-2019 vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and people over 70.UK authorities have placed orders for 100 million doses of the vaccine – enough to vaccinate most of the population – should it receive regulatory approval.In the phase two trials, volunteers received two doses of the vaccine candidate, or a placebo meningitis vaccine.According to the researchers, volunteers in the trial who received.